PDUFA Date for Lenacapavir

Jun 30, 2025, 7:00:00 AM — fda decision

fda decision

Summary

The FDA has set a PDUFA date for lenacapavir, a drug for HIV prevention, which is anticipated to be a significant milestone for Gilead.

Company

GILEAD SCIENCES INC (GILD)

NASDAQ — Healthcare: Manufacturing, Drug Manufacturers - General: Biological Products (No Disgnostic Substances)

www.gilead.com

Similar Events

Jul 28, 2025, 4:00:00 AM

FDA PDUFA Target Action Date for EMPAVELI®

The FDA has set a PDUFA target action date of July 28, 2025, for the supplemental New Drug Application of EMPAVELI® for treating C3 glomerulopathy and IC-MPGN.

fda decision
Sep 25, 2025, 12:00:00 AM

FDA PDUFA Target Action Date for Paltusotine

The FDA has set a PDUFA target action date of September 25, 2025, for paltusotine's New Drug Application, marking a critical step towards its approval for acromegaly treatment.

fda decision
Jul 22, 2025, 5:00:00 AM

PDUFA Date for RP1

The FDA has set a PDUFA date of July 22, 2025, for Replimune's RP1, a significant milestone in the regulatory process for this oncolytic immunotherapy.

fda decision
Aug 8, 2025, 5:00:00 AM

PDUFA Target Action Date for LNZ100

The FDA has set a PDUFA target action date of August 8, 2025, for LNZ100, a treatment for presbyopia, with commercial launch activities expected to commence immediately upon approval.

fda decision